Previous 10 | Next 10 |
I have kept a close eye on Global Blood Therapeutics ( GBT ) over the past year and have come close to clicking the Buy button on multiple occasions. However, I always had a reason to hold off and retreat. The company’s recently publicized Voxelotor’s Phase III results in sickl...
The wise investor recognizes that success is a process of continually seeking answers to new questions. - Sir John Templeton It's interesting to observe that the financial community sometimes demands companies to innovate drugs that deliver a cure. In reality, many chronic conditions can o...
Introduction Global Blood Therapeutics ( GBT ) recently reported top-line results of its Phase III HOPE U.S. clinical study of Voxelotor in patients with Sickle Cell Disease or SCD. Following the positive phase III HOPE study clinical trial results on June 14, 2019, the stock price surged ov...
Global Blood Therapeutics (NASDAQ: GBT ) prices its public offering of ~3.4M common shares at ~$59.25, expected to yield gross proceeds of ~$200M. Closing date is June 28. More news on: Global Blood Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
OncoCyte (NYSEMKT: OCX ) -21% . More news on: OncoCyte Corporation, Liberty Latin America Ltd., Oxbridge Re Holdings Limited, Stocks on the move, Read more ...
SOUTH SAN FRANCISCO, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today a...
Global Blood Therapeutics ( GBT ) announced positive results from its phase 3 study using Voxelotor to treat patients with sickle cell disease ((SCD)). These latest positive results reinforce the company's plans to complete its rolling submission for the drug by the 2nd half of 2019....
Biotech Pulse Biotech shares are up this year, as represented by the Nasdaq Biotechnology Index ( IBB ), which is the industry benchmark, and the S&P Select Biotechnology Index ( XBI ), after a sharp decline in 2018. This is a welcome respite for biotech investors. However, it has not ...
Today's selloff in Global Blood Therapeutics ( GBT -6.2% ) is overdone , Piper Jaffray analyst Danielle Brill says after further clarification from today's voxelotor results , particularly for vaso-occlusive crises, appear more in-line relative to previous reports. More news on: Global...
Global Blood Therapeutics (NASDAQ: GBT ) is 3.7% lower after posting data in the New England Journal of Medicine showing its sickle cell disease drug met primary endpoints . More news on: Global Blood Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...